Cardioprotective therapy consisting of an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker and a beta-blocker, preferably carvedilol, is recommended (Class IIa) for secondary prevention of both symptomatic and asymptomatic cancer patients developing cardiac dysfunction [defined as a reduction of left ventricular ejection fraction (LVEF) ≥ 10%] according to guidelines for HF (6, 41, 42). The gene discussed is ACE; the disease is cancer.